Olympus Recalls ShockPulse-SE Lithotripsy System Reusable Probes Due to Recognition Issues
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
Olympus Corporation of the Americas has initiated a voluntary recall of 602 ShockPulse-SE Lithotripsy System Reusable Probes due to a defect where the generator fails to recognize the transducer.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 2, 2026 and geographically references Worldwide. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — FDA Recalls — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, fda, MedicalDevice) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What Happened
Olympus Corporation of the Americas has initiated a voluntary recall of the ShockPulse-SE Lithotripsy System Reusable Probes. Ongoing investigations identified instances where the device generator remains in a "blinking phase" while waiting to recognize the transducer. This malfunction is caused by damage to the transducer plug and/or the generator receptacle, which prevents the system from functioning as intended.
Which Products Are Affected
The recall affects the following medical device components:
- Brand Name: ShockPulse-SE Lithotripsy System SPL-SR
- Product Name: ShockPulse-SE Lithotripsy System - Reusable Probes
- Model/Catalog Number: SPL-SR
- UDI: 00821925043824
- Serial Numbers: All serial numbers are included
- Quantity: 602 units
This recall impacts products distributed worldwide, including the United States, Canada, Mexico, Bolivia, Chile, India, China, the European Union, Singapore, Australia, Korea, and Japan.
What You Should Do
The recall was initiated via a notification letter to affected customers. Healthcare facilities and providers using the ShockPulse-SE Lithotripsy System should inspect their equipment for damage to the transducer plug or generator receptacle. If the generator remains in a blinking phase and fails to recognize the transducer, the device should not be used. For further information regarding returns or technical support, contact Olympus Corporation of the Americas at their Center Valley, PA headquarters.
Why This Matters
The ShockPulse Lithotripsy System is a critical electromechanical device used to fragment calculi and aspirate stone debris during medical procedures. A failure of the generator to recognize the transducer can lead to procedural delays or the inability to perform the lithotripsy as required.
Source
Information provided by the FDA under Recall Number Z-1477-2026.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.
What is this FDA recall about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more FDA Recalls updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category